Empower Pharmacy (Empower Clinic Services, LLC), Houston, TX
Is Empower Pharmacy (Empower Clinic Services, LLC) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.
Does Empower Pharmacy (Empower Clinic Services, LLC) hold a Texas pharmacy license?
The Texas State Board of Pharmacy lists license 26444 for EMPOWER PHARMACY, HOUSTON, status Active, as of Nov 15, 2026. The California State Board of Pharmacy also lists nonresident license NRP 2567 for Empower Pharmacy, Houston, TX, status Active and license NSC 101695 for Empower Pharmacy, Houston, TX, status Delinquent, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 6131 for Empower Pharmacy, Houston, TX, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054018298 for EMPOWER CLINIC SERVICES LLC, HOUSTON, TX, status ACTIVE and license 054021486 for EMPOWER CLINIC SERVICES LLC, HOUSTON, TX, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002564 for EMPOWER PHARMACY, HOUSTON, TX, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0001344 for Empower Clinic Services, L.L.C., HOUSTON, TX, status Active, license AA-0000030 for Empower Clinic Services, L.L.C., HOUSTON, TX, status Active and license A9-0002430 for Empower Pharmacy, HOUSTON, TX, status Expired, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012675 for Empower Clinic Services, LLC, Houston, TX, status Active, license 5301012722 for Empower Clinic Services, L.L.C., Houston, TX, status Active and license 5301013382 for Empower Clinic Services, L.L.C., Houston, TX, status Active, as of Nov 10, 2026.
Has Empower Pharmacy (Empower Clinic Services, LLC) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 4 warning letters (Oct 15, 2021, 2 on Apr 2, 2025 and Sep 18, 2026), 1 untitled letter (Jul 22, 2019) and 1 FMD-145 letter (Apr 2, 2019) for Empower Pharmacy (Empower Clinic Services, LLC). FDA’s posted warning letters that name a GLP-1 drug include one to Empower Clinic Services, LLC dba Empower Pharmacy, dated Sep 18, 2026. State board actions: the Texas State Board of Pharmacy file dated Nov 15, 2026 does not mark prior disciplinary orders on license 26444. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists 4 actions: “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for four years subject to the terms and conditions in the decision” dated Jan 18, 2023, case AC 7117 on nonresident license NRP 2567, “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended” dated Jan 18, 2023, case AC 7117 on nonresident license NRP 1834 and “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for four years subject to the terms and conditions in the decision” dated Jan 18, 2023, case AC 7117 on nonresident license NSC 101695, and more listed below. The Colorado State Board of Pharmacy’s license dataset also lists 2 actions: “CLS Stipulation” dated Aug 8, 2023, case 2023-1306 on nonresident license OSP 6131 and “CLS Letter of Admonition” dated Oct 12, 2021, case 2021-3810 on nonresident license OSP 6131. The Illinois Department of Financial and Professional Regulation’s license dataset also lists “Reprimand” dated Jun 21, 2024, case 2022008353 on nonresident license 054018298.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Empower Clinic Services, LLC; Empower Pharmacy
- Location
- Houston, TX
- Type as FDA labels it
- 503A and 503B
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 7
- Warning letters on FDA’s actions page
- 4
- Latest action on that page
- Sep 18, 2026
- FDA Data Dashboard inspections
- 8 inspections: 7 OAI, 1 VAI; 9 published Form 483s
- Form 483 text on this page
- 8 Form 483s, 70 observations
- State board records
- License found: 26444, Active
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy under 2 entries in the same city (Empower Clinic Services, LLC, (dba Empower Pharmacy), 503A; Empower Clinic Services, LLC, (dba Empower Pharmacy), 503B), with 14 distinct dated actions between them.
| Document | |||
|---|---|---|---|
| Sep 18, 2026 | Warning letter | Warning Letter Issued 09/18/2026 | fda.gov |
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Apr 2, 2025 | Warning letter | Warning Letter Issued 04/02/2025 | fda.gov |
| Apr 2, 2025 | Warning letter | Warning Letter Issued 04/02/2025 | FDA copy (archived) |
| Oct 4, 2024 | Form 483 | 483 Issued 10/04/2024 | FDA copy (archived) |
| Aug 28, 2024 | Form 483 | 483 Issued 08/28/2024 | FDA copy (archived) |
| Dec 1, 2023 | Form 483 | 483 Issued 12/01/2023 | FDA copy (archived) |
| May 4, 2023 | Regulatory meeting | Regulatory Meeting Held 05/04/2023 | Not linked by FDA |
| Aug 5, 2022 | Form 483 | 483 Issued 08/05/2022 | FDA copy (archived) |
| Oct 15, 2021 | Warning letter | Warning Letter (10/15/2021) | FDA copy (archived) |
| Mar 6, 2020 | Form 483 | 483 Issued 03/06/2020 | FDA copy (archived) |
| Jul 22, 2019 | Untitled letter | Untitled Letter Issued 07/22/2019 | FDA copy (archived) |
| Apr 2, 2019 | FMD-145 letter | FMD-145 Letter Issued 04/02/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Empower Clinic Services LLC, Houston, TX (FEI number 3011887629); Empower Clinic Services, LLC, Houston, TX (FEI number 3021758709), matched to this page by exact name, city and state. It lists 8 inspections: 7 OAI, 1 VAI at those sites, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile (FEI 3011887629). Dashboard firm profile (FEI 3021758709).
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Nov 14, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3021758709 | 1287888 |
| Oct 4, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3021758709 | 1251190 |
| Aug 28, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011887629 | 1229660 |
| Dec 1, 2023 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3021758709 | 1223951 |
| Aug 5, 2022 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011887629 | 1177181 |
| Mar 6, 2020 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011887629 | 1121143 |
| Jan 24, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011887629 | 1039826 |
| Nov 25, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011887629 | 948619 |
Form 483s FDA has published for these sites
- Dec 14, 2025: Form 483 to Empower Clinic Services LLC, published Jan 27, 2026. fda.gov
- Nov 14, 2025: Form 483 to Empower Clinic Services, LLC, published Dec 18, 2025. fda.gov
- Oct 4, 2024: Form 483 to Empower Clinic Services, LLC, published Feb 7, 2025. fda.gov
- Aug 28, 2024: Form 483 to Empower Clinic Services LLC, published Oct 11, 2024. fda.gov
- Dec 1, 2023: Form 483 to Empower Clinic Services, LLC, published Feb 12, 2024. fda.gov
- Aug 5, 2022: Form 483 to Empower Clinic Services LLC, published Oct 11, 2022. fda.gov
- Mar 6, 2020: Form 483 to Empower Clinic Services LLC, published May 4, 2020. fda.gov
- Oct 24, 2018: Form 483 to Empower Clinic Services LLC, published Jan 17, 2024. fda.gov
- Aug 22, 2016: Form 483 to Empower Clinic Services LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 70 numbered observations in all, across 8 inspections ending Nov 25, 2015 to Nov 14, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 3, 2025 to Nov 14, 2025: 6 observations
- Firm on the cover
- Empower Clinic Services, LLC dba Empower Pharmacy, 7601 N Sam Houston Pkwy W Ste 100, Houston, TX 77064-3595
- FEI number
- 3021758709
- Establishment type on the cover
- Producer of Sterile and Non-sterile Drug Products
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from 503B list, actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Microbial contamination was present in the ISO <Redacted B4> area.
Specifically, during a review of selected non-conformance reports, NC-00230)documented on August 21, 2024, at approximately 0925, a viable air sample collected from Location <Redacted B4> within ISO Class <Redacted B4> Filling Room 1267 recovered one (I) colony-forming unit (CFU during routine <Redacted B4> environmental monitoring (EM) activities ( exceed action limit of <Redacted B4> for ISO <RedactedB4> environments). Testosterone Cypionate in GSO Injection, 200 mg/mL (5 mL fill volume ., Lot #202364, BUD 5/28/2025, Qty. <Redacted B4> vials was being filled using the <Redacted B4> Filler. Your firm failed to adequately control microbial contamination within your firm's ISO <Redacted B4> rooms. Your firm's investigation documented the microbial was introduced by a technician introducing the contamination by hand or body positioning during setup in the ISO environment: or from an operator being in close proximity to the sampling site while performing an aseptic intervention. The batch was further processed, accepted by quality, and dispensed for patient specific prescriptions.
Observation 2
Failure to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO <Redacted B4> area.
Specifically,
A. During observation of the filling setup for the finished sterile drug, L-Camitine (30mL) 500 mg/ml, Lot # 221071, BUD 1/2/2026, Qty. <Redacted B4> units, in ISO <Redacted B4> Formulation Room <Redacted B4>. (Non-sterile Compounding Suite <Redacted B4>), a technician failed to disinfect <Redacted B4> scissors with <Redacted B4> after removing from ISO <Redacted B4> BSC, using them within the ISO <Redacted B4> Cleanroom, then returning them to the ISO <Redacted B4> BSC.
B. Sterile compounding technician was observed failing to disinfect sterile gloves after performing task within ISO <Redacted B4> Cleanroom prior to returning to the ISO <Redacted B4> BSC, while setting up L-Carnitine (30mL),500 mg/ml, Lot# 22107~BUD 1/2/2026, Qty <Redacted B4>. lb) <Redacted B4> in ISO <Redacted B4> Formulation Room (Non-sterile Compounding Suite <Redacted B4>
C. ...
Observation 3
Specifically, during, observation of the firm's manual aseptic filling and stoppering within ISO <Redacted B4> Formulation Room <Redacted B4> (Non-hazardous drug formulation and filling) and ISO <Redacted B4> Formulation Room (Hazardous drug formulation and filling) within <Redacted B4> air flow ISO ., BSCs, technicians were observed disrupting "first air" during filling and capping open vials by holding the hand that is not in use with an open palm up potentially disrupting unidirectional air flow. Similar hand/palm orientation technique was observed in the firm's April 2025 recorded smoke studies, E4996-MF-7.mp4, E4996-MF-6.mp4, and E4689-MF-7.mp4.
Observation 4
Personnel were observed moving quickly in a critical area or in an area immediately adjacent to a critical area likely causing disruption of unidirectional airflow.
Specifically, during observations of the <Redacted B4> Filler production equipment setup, sterile batch filling/capping, and cleaning of the sterile drug product, Tirzepatide/ Niacinamide (4 mL) 17 / 2 mg/mL, Lot# 221077, BUD 2/1/2026, Qty. <Redacted B4> vials, technicians within the ISO <Redacted B4> Filling Cleanroom while performing wipe down interventions of the doors and sidewalls used a rapid wipe down method (rapid back and forth strokes) potentially disrupting unidirectional flow.
Observation 5
Smoke studies were inadequately performed under dynamic conditions.
Specifically, your firm's April 2025 ISO <Redacted B4> cleanroom smoke studies failed to include the intervention involving the <Redacted B4> Filler equipment setup, sterile filling/capping, and cleaning disinfection method used for wiping down unit doors and sidewalls during production of sterile drug products used a rapid wipe down method (rapid back and forth strokes) potentially disrupting unidirectional flow within the ISO <Redacted B4> Cleanroom during dynamic conditions. This is a repeat Observation.
unidirectional flow within the ISO □ Cleamoom during dynamic conditions. This is a repeat Observation.
Observation 6
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically, your firm's media fills failed to reflect actual production sizes based on vial fill/size. For example, during review of the firm's report, Summary Report ml <Redacted B4> Media Fill Report and Protocol, A-REP-SCP-0003 dated 30-May-2025 reported filling of <Redacted B4> vials verse the maximum of <Redacted B4> vials with a fill volume of <Redacted B4> mL. Documented within the procedure, A-SOP-SCP-0011, Aseptic <Redacted B4> process verification <Redacted B4> 1 mL vial <Redacted B4> is used for <Redacted B4> volumes ranging from <Redacted B4> mL <Redacted B4> mL with a Theoretical Batch Size of <Redacted B4> vials. A review of firm's production records since the previous FDA inspection, found Tirzepatide /Niacinamide Injection 8/2 mg/mL, Lot 218493 Compounded 9/17 /2022 <Redacted B4> Expiiy 6/14/2026 reported a Theoretical Batch Size of <Redacted B4> vials with an actual released quantity <Redacted B4> vials with a fill volume of <Redacted B4> mL. ...
Inspection Nov 10, 2025: 9 observations
- Firm on the cover
- Empower Clinic Services, L.L.C. dba Empower Pharma, 5980 W Sam Houston Pkwy N Ste 300, Houston, TX 77041
- FEI number
- 3011887629
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- One Main Place 1201 Main Street Ste 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically,
A. Aseptic process simulations (APS) are not adequately designed or controlled to demonstrate that aseptic operations can consistently prevent microbiological contamination of sterile drug products. For example,
1. Your aseptic process simulations do not encompass the full aseptic process, as formulation, <Redacted B4> and <Redacted B4> filling operations are performed and qualified separately rather than as a single integrated simulation reflective of routine production. For example, products such as Ascorbic Acid Preserved 200 mg/mL (30 mL) require a sequential series of events, to include formulation of the bulk, transfer to <Redacted B4> and transfer to <Redacted B4> /Filling. Rather, your current APS breaks these steps into separate activities and evaluates growth or turbidity only at the <Redacted B4> filling step, without simulating or assessing upstream aseptic manipulations. As a result, contamination risks associated with these routine upstream manipulations are not challenged. ...
Observation 2
Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
Specifically,
A. Your visual inspection program lacks adequate controls and scientific justification to ensure consistent detection and evaluation of product defects, including, but not limited to, the following:
18:18:0S-06'00'
2. Procedure B-SOP-VIL-0003, Visual Inspection of Injectables, Revision 012, Effective Date 28-May-2025, outlines a process in which lots that exceed preset defect limits during the initial 100% inspection are <Redacted B4> AQL sampling is conducted <Redacted B4>. Nonconformances (NCs) are initiated only when a batch fails AQL for critical defects or when the total reject rate is exceeded during 100% inspection. Failures involving major or minor defect categories do not generate an NC, and the lot is instead subjected to additional 100% inspection without investigation or documented justification.
3. Defect classifications (critical, major, minor) are not scientifically supported. ...
Observation 3
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specification whether or not the batch has been already distributed.
Specifically,
A. Your firm implemented a change under CHR-0000005416 to reduce the retention timeframe for aseptic operation records based on reported "poor practices" and untimely investigation activities by quality personnel, however, no nonconformance, or CAPA had been generated to document, evaluate, or substantiate these behaviors within the quality system. As a result, a quality impacting change was made without supporting documentation, data, or risk assessment.
B. From 08/29/2024 to present, approximately 337 of approximately 963 nonconformance report s (NCs) (which include nonconformances, deviations, and OOSs) remained open, several of whi ch were associated with, but not limited to, batch rejections, EM recoveries, and AQL failur es related to extrinsic particles and glass defects. ...
Observation 4
Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions
Specifically,
Per the firm's procedure B-SOP-STR-0004, titled "Cleaning and Disinfection of the Cleanroom", Revision 017, effective date 10/05/2025. Section 6.7.4. following HD injectable formulation in Room <Redacted B4>, the room <Redacted B4> and clean HD substances prior to resuming the subsequent operations as stated below:
- "If injectable formulation lots consisting of different actives are scheduled to be formulated consecutively (ex: Testosterone Cypionate and Estradiol Cypionate), <Redacted B4> cleaning shall be completed prior to the formulation of different active sterile injectable lots.
Upon review of the cleaning records for Room <Redacted B4> (HD Fill <Redacted B4> Finish Room <Redacted B4> the following was observed:
1. Qn <Redacted B4> Testosterone Cypionate IN GSO (5 ML), Lot 614031, was formulated in Room <Redacted B4> followed by the formulation of Nandrolone Decanoate IN GSO (5 ML), Lot 613969. A <Redacted B4> cleaning was not performed between the two formulations as required by the firm's cleaning procedure. ...
Observation 5
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically,
Date: 202s.11.1 4 1s,21:33-06'oo·
1. Non-sterile Hazardous (HD) drug mixing and formulation is performed using Mixer (EQ ID: <Redacted B4> that is located outside the Containment Primary Engineering Control (C-PEC) m Room <Redacted B4> in HD Fill-Finish Room <Redacted B4>).
2. The remaining phases of the compounding of HD drug products occur in rooms that host <Redacted B4> and filling operations for both HD and non-HD drug products, including Sterile . <Redacted B4> in Room <Redacted B4> and Sterile <Redacted B4> and Filling in Room <Redacted B4>. Both Rms <Redacted B4> and <Redacted B4> operate under positive pressure and are not equipped with external exhaust vents through which air is exhausted directly to the outside of the building without recirculation.
3. Per section 6.2 of the firm's procedure B-SOP-STR-0002: "HD drug products shall only be brought out of the Formulation Room in sealed containers such as IV bags". ...
Observation 6
Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
Specifically,
Your firm failed to establish validated hold-times for sterilized bulk drug products to mitigate the risk of contamination of finished drug products.
For example,
The variability in the number of days the drug product is held between the first <Redacted B4> and the second <Redacted B4> and filling steps of the production process is described in the following table:
Drug products filled in IV bags after the first <Redacted B4> are stored on the shelves in the ISO <Redactd B4> Room.
Observation 7
HEPA filters are not sealed around the perimeter.
Date: 2025.11.1 4 THIS PAGE -$ 18:23:0S -06'00'
4 The HEPA filters in the ISO O F01mulation Room (Room 'f ) and ISO K6) (21-) Iand Filling Room (Roo~ ), where sterile compounding occur, were not properly sealed. The perimeter of the HEP A filter did not fully overlap with the ceiling. The filters were not adequately sealed and had ~aps. A jagged and uneven grating was also observed along the seams of one HEP A filter in Room 4 bl < l . For example, the work order (No. 42980) indicates that maintenance work (re-caulk) was perfo1med along the seams of HEPA filters in Room 1 7 Ilil " on 07/05/2024. The last two requalification records for the HEPA filters (conducted in July 2025 and December 2024) documented passing results for all HEPA filters in Room 4 t1>ll l, even though grating around the HEP A filter was noted during the inspection walkthrough on 11/03/2025. During the inspection, we observed the following production activities:
• Formulation of Ascorbic Acid Preserved 200 MG/ML (30 ML) Injectable Vials, Lot 615360, was pe~formed in Room <Redacted B4> on 11/05/2025. ...
Observation 8
Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier's test analyses at appropriate intervals.
Specifically,
byJOOHI CASTELV CASTELVETERE-S THIS PAGE
Date: ETERE -5 2025.11.14 1s:23:31-06w
B. Certificates of Analysis from the suppliers of the Ready-to-Use sterile single-use critical materials for drug product formulation <Redacted B4> and filling bag are accepted without verifying test results for sterility initially and periodically.
C. Your firm does not audit any of your ready to use sterile single use critical material suppliers.
Observation 9
The written stability program for drug products does not include reliable, meaningful and specific test methods.
Specifically,
A. The methods used during stability testing have not been demonstrated to be stability indicating. Although limited stress studies were performed by your contract laboratories, they did not include sufficient evaluation of degradation products or impurities. In addition, you do not review the method validation data to confnm that these methods are stability indicating before approving and using them for stability testing. As a result, you do not ensure that the stability methods can detect and quantify all potential impurities and degradation products that may form over time.
Name not shown-5 ...
Inspection Sep 24, 2024 to Oct 4, 2024: 8 observations
- Firm on the cover
- Empower Clinic Services, LLC dba Empower Pharmacy, 7601 N Sam Houston Pkwy W Ste 100, Houston, TX 77064-3595
- FEI number
- 3021758709
- Establishment type on the cover
- Producer of Sterile and Non -sterile drug products
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.
Specifically, you have not demonstrated to ensure hazardous drugs do not contaminate non-hazardous drugs compounded within your cleanroom environment. Currently, the <Redacted B4> lfilling line in the ISO-5 room, which consists of <Redacted B4> design under <Redacted B4> pressure, is used for both hazardous and non-hazardous drug production. These drug types can be processed one after another, where on some occasions, the processing of both non-hazardous and hazardous drugs occur on the same day. This is also the case for your <Redacted B4> filled vials that utilize the <Redacted B4> ISO-5 laminar flow hoods located in Formulation Room LJ to perform these activities. You rely on your cleaning validation to support this practice; however, this validation does not consist of containment studies that demonstrate you can effectively prevent cross contamination between these drug types.
Observation 2
Production areas have difficult to clean or contain porous, particle generating, or visibly dirty equipment or surfaces.
Specifically, on 9/25/2024, we observed the following inside your firm's ISO-5 classified cleanroom, where human drug products are aseptically filled:
1. What appears to be rust on the outlets in the ISO-5 classified cleanroom and adjacent to your firm's ISO-5 classified <Redacted B4> filling line.
2. What appears to be rust above the wheel ofthe cart located inside the ISO-5 cleanroom adjacent from the ISO-5 classified <RedacteB4> filling line.
3. What appears to be chipped metal particles on the outlets in the ISO5 classified cleanroom.
4. Multiple dents and chips observed on the walls next and adjacent to the ISO-5 <Redacted B4> filling line located in the ISO-5 classified cleanroom.
5. A loose gasket hanging above the opening of the <Redacted B4> inside the ISO-5 classified cleanroom where exposed <Redacted B4> vials are loaded.
n
6. Caulking above the opening of your firm's <Redacted B4> located in the ISO-5 classified cleanroom where the <Redacted B4> stainless steel meets the wall appears to be not smooth and not easily cleanable.
7. ...
Observation 3
Lack of routine certification of the ISO 5 area.
Specifically,
I. The certifications 7 performed in October 2023 and April 2024 for your ISO-5 room used for <Redacted B4> filling and <Redacted B4> of sterile vials does not include an evaluation of particulate counts (non-viable analysis) for eight (8) of the <Redacted B4> HEPA filters intended to provide ISO-5 class air quality. These eight (8) HEP As are located directly over the filling line. Additionally, your routine environmental monitoring does not include the performance of air viable and non-viable within this filling space.
2. Throughout operations on 09/25/2024 for the filling of Gonadorelin lmg/ml, lot 203759, BUD 03/24/2025, we observed the door within the ISO 7 room leading into the ISO-5 room opened at least 10 times to either communicate with operators or to retrieve supplies. The firm has not demonstrated through either room certification, smoke studies, environmental monitoring, or media fills this practice does not compromise the quality of first pass air intended for maintaining drug sterility.
Observation 4
Failure to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO 5 area.
Specifically,
1) For the <Redacted B4> filling line located in your ISO-5 room, you do not have scientific rationale to support not sterilizing all product contact surfaces such as the stopper sorting bowl, supply hopper and insertion station that come into direct contact with sterile vials. Currently, the referenced surfaces are decontaminated by chemical disinfectants. These items comprise of the container closure systems used for parenteral drug products purported to be sterile.
2. During cleaning of your ISO-5 classified room and ISO-5 classified <Redacted B4> filling line, your firm failed to meet the established contact ( dwell) time of <Redacted B4> for your sporicidal agent, <Redacted B4>. On 09/27/2024, we observed the <Redacted B4> applied to surfaces in the ISO-5 classified room and ISO-5 classified <Redacted B4> filling line dry after approximately 3 minutes without being reapplied by the operator to meet the established contact ( dwell) time. ...
Observation 5
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically, for your <Redacted B4> operations, you do not have scientific rationale to support compounding a maximum batch size of <Redacted B4> vials. The largest batch size most recently produced by your facility was <Redacted B4> vials on 09/23/2024 for Tirzepatide/Niacinarnide (2. 5 mL) 8/2mg/ml. Your most recent media fill performed 05/02/2024 a Q proved 05/21/2024 challenged a maximum batch size of <Redacted B4> vials. The most recent media fill for <Redacted B4> vials was approved 12/21/2022 challenged a maximum batch size of the <Redacted B4> vials. Additionally, your media fills are not designed to qualify operators as suitable for performing these operations since this is determined by your personnel media fills evaluating <Redacted B4> vialing operations and not <Redacted B4> operations. <Redacted B4> vialing operations was last performed in your organization 05/2022.
Observation 6
Inadequate routine environmental monitoring in the ISO 5 area.
Specifically, you do not have scientific rationale to support your action limit/specification for surface sampling of your ISO-5 designated areas as greater than or equal to <Redacted B4> colony forming units (CFU)s as opposed to less than one (1) colony forming unit. For example, you recovered too numerous to count (TNTC) CFUs from surface sampling of the <Redacted B4> internally identified as VSS40 inside the ISO-5 classified cleanroom during the aseptic filling of Semaglutide/Cyanocobalmin (2.5ml) 5/0.Smg/ml, lot#199411 BUD: 04/09/2025. After identifiying the organism as Paenibacillus lautus, a spore former, your firm's quality unit proceeded to approved the entire batch on the premise that this is not <Redacted B4> product.
Observation 7
Smoke studies were not and were inadequately performed under dynamic conditions.
Specifically, you failed to perform adequate smoke studies of your ISO-5 classified room including but not limited to your ISO-5 classified <Redacted B4> filling line, where finished drug products are aseptically filled, to assess whether proper particle control dynamics have been achieved throughout the critical area. This was evidence by the airflow patterns during aseptic interventions and providing mitigation in circumstances where air turbulence/eddy currents and stagnant air were depicted. Your smoke studies conducted April 2024 of your firm's ISQ-5 classified <Redacted B4> Formulation <Redacted B4> and ISO-5 classified <Redacted B4> Formulation failed to demonstrate unidirectional airflow in your aseptic operations. Examples of deficiencies reference above include but not limited to the items tabulated below:
Observation 8
Use of ingredients not intended for phannaceutical use in non-sterile drug production.
Specifically, you used non-pharmaceutical grade Azelaic Acid, Lot <Redacted B4> expiration date 09/15/2026, as an ingredient in the production of non-sterile drug products including but not limited to: Anti-Aging Ultra, Lot 203734, BUD 12/22/2024. The Azelaic Acid, Lot <Redacted B4> expiration date 09/15/2026, used to produce Anti-Aging Ultra, Lot 203734, BUD 12122Jzo24, is labeled as cosmetic grade. Your firm release a quantity of <Redacted B4> units in interstate commerce.
~J
Inspection Aug 1, 2024 to Aug 28, 2024: 9 observations
- Firm on the cover
- Empower Pharmacy, 5980 W Sam Houston Pkwy N Ste 300, Houston, TX 77041-5254
- FEI number
- 3011887629
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-244 5
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically,
A. Your firm released a batch of a sterile product even though positive microbial growth was detected during environmental monitoring within the ISO 5 production area. During the aseptic filling of Pyridoxine HCL, Lot <Redacted B4> , Compounding Date 4/18/2024, BUD 4/1 8/2025, Batch Size <Redacted B4> EM identified 1 CFU of Bacillus altitudinis/pumilus/safensis on a surface contact plate inside the ISO 5 LAFH, Equipment ID: E2150, however, the batch was released and distributed to customers.
B. The sterile inner layer of bags containing vials was routinely opened in the ISO 7 filling room and introduced into the ISO 5 LAFH without being disinfected. On 8/1/2024, during the production of Gl cine 50 mg/ml, Lot# <Redacted B4>, BUD: 7/30/2025, Batch Size: <Redacted B4> vials, it was observed that the <Redacted B4> operator cut open the outer layer of a vial bag and introduced the sterile inner bag into the ISO 5 LAFH, Equipment ID: E2150 without disinfection. ...
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
A. Investigation of complaints on lack of efficacy was inadequate. Your firm has received approximately 20 complaints for lack of efficacy of compounded drug products since August, 2022. The investigation of each complaint did not identify any deficiencies in production, and no returned samples were received; However, your firm did not test any retention samples for complaints related to lack of efficacy as part of your investigation process. For example, your firm received complaints for lack of efficacy for Testosterone 200 mg Pellet, Lot # <Redacted B4> Lot# <Redacted B4> dated 5/16/2023 per COM-0000001217, Testosterone 200 mg Pellet, Lot <Redacted B4> dated 5/22/2023 per COM-0000001233 and Ketamine HCl Preserved l00mg/mL Injection (l0mL), Lot# <Redacted B4> dated 10/24/2022 per CPOM-0000000382. The retention samples have not been tested for these complaints.
B. Investigation of EM OOS during aseptic batch processing was inadequate. ...
Observation 3
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically,
On 8/1/2024, during the walkthrough of the microbiology laboratory, it was observed that all EM <Redacted B4> plates were placed in <Redacted B4> 1 bag for incubation without any visible gas. For example, the EM plates for zinc sulfate 10 MG L ZINC, lot # <Redacted B4> were laced in <Redacted B4> bag for incubation. Currently, all EM samples were placed in <Redacted B4> for microbial growth testing. Your growth promotion testing was conducted in a contract laboratory. There is no documented <Redacted B4> evidence or study demonstrating the impact of this practice on bacterial and fungal growth.
Observation 4
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Specifically,
A. During the visual inspection of Ketamine HCL Preserved 100 mg/ml, Lot <Redacted B4> BUD:1/27/2025, Batch Size: <Redacted B4> vials on 8/1/2024, it was observed that visual inspectors did not <Redacted B4> the vials, as requirea 6y the Visual Inspection Procedure for Visual Inspection, Document Number: B-SOP-VIL-0003. The same practice was observed during the production of Glutathione Preservative-Free 200 mg/mL, Loti <Redacted B4> BUD: 1/27/2025, Batch Size: <Redacted B4> vials on 8/2/2024.
(4 l
B. During the visual inspection of Ketamine HCL Preserved 100 mg/mL, Lot# <Redacted B4> it was observed that the inspector <Redacted B4> a the vials in a manner that caused bubbles to form, potentially interfering with the inspection. However, Section 6.3.6.2 <Redacted B4> of the Visual Inspection Procedure Document Number: B-SOP-VIL-0003 specifies: <Redacted B4>
AMENDMENT 1
Observation 5
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
Specifically,
A. Your firm does not adequately maintain your ISO-5 hoods used to produce stelile drug products. On 8/12/2024, discolored stains were observed on the HEPA filter inside your ISO -5 hood (Equipment <Redacted B4>°. Additionally, discolored stains were observed <Redacted B4> ISO -5 hoods (Equipment ID:: <Redacted B4> ) and on the legs on the ISO -5 hood (Equipment ID: <Redacted B4>
B. On 08/12/2024, scratches were obse1ved inside ISO -5 hoods (Equipment IDs: <Redacted B4>. The scratches do not appear to be smooth and cleanable for aseptic operations.
Observation 6
Adverse reactions were not reported to FDA using form FDA 3500A within 15 calendar days of initial receipt of information.
Specifically,
Your outsourcing facility has not submitted an adverse event report to FDA in accordance with the content and format requirements established through guidance or regulation under 21 CFR 310.305 as required by section 503B(b)(5). Your firm received a serious adverse event on July 29, 2022, concerning a patient who experienced hypersensitivity reactions following an intravenous (IV) infusion of ascorbic acid, methylcobalamin, and bacteriostatic water. This adverse event was reported to FDA on September 2, 2022 (FAERS #21290234).
AM ENDMEN T 1
Observation 7
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A. Personnel monitoring performed do not accurately represent the enviromnent in which sterile drug product are filled. Your procedure B-SOP-QC-0002, Personnel Monitoring Program, Revision 001 , Effective date: 2-Jan-2024, Section 6.2.1 instructs that personnel monitoring <Redacted B4>
i. Aseptic operators working in, <Redacted B4> ISO -5 hoods (Equipment ID <Redacted B4> & <Redacted B4> were observed on 7/31/2024 sanitizing_ their gloves prior to performing personnel monitoring. Your Operators failed to <Redacted B4> aseptic fillinf of sterile drufg product. Lipo-B/Metliiomne Chlorine Chloride Cyanocobalamin 25/50/1 mg/mL Injection Solution Lot <Redacted B4> BUD: 27 Jan 2025, as required by your procedure.
ii .Aseptic operators working in ISO - 5 hood (Equipment ID: E2151) were observed on 7/31/2024
sanitizing their gloves prior to perform personnel monitoring. Your Operators failed to aseptic filling of sterile drug product Testosterone <Redacted B4> Cypionate 200mg/mL Lot <Redacted B4>, BUD: 10 Jul 2025, as required by your procedure. ...
Observation 8
The container of your outsourcing facility's drug products does not include information required by section 503B(a)(IO)(B) of the Federal Food, Drug and Cosmetic Act (FD&C Act).
Specifically,
I The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(IO)(B). Specifically, your containers do not include the following information.
a) Information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1088. Examples of your container labels that do not contain this information:
□ Glycine Injectable Solution 50 mg/mL (30 mL)
AM ENDMEN T 1
b Directions for use, including, as appropriate, dosage and administration. Examples of your container labels that do not contain this information:
□ Glycine Injectable Solution 50 mg/mL (30 mL)
Observation 9
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
A. The validation of disinfectant efficac was inadequate. Your firm conducted a disinfectant efficacy study of <Redacted B4> Formula in 2017, which only covered materials such as <Redacted B4>. However this study did not include surfaces like those of bags containing vials or supplies (e.g., Formula is used to disinfect surfaces of supplies when transferring hem from <Redacted B4> area.
B. Your firm failed to perform a cleaning validation for the cleaning of the following equipment used in compounding your sterile pellet drug products Testosterone and Estradiol:
AMENDMENT 1
Inspection Oct 16, 2023 to Dec 1, 2023: 8 observations
- Firm on the cover
- EMPOWER CLINIC SERVICES, LLC, dba Empower Pharmacy, 7601 N Sam Houston Pkwy W Ste 100, Houston, TX 77064 -3595
- FEI number
- 3021758709
- Establishment type on the cover
- Producer of Sterile and Non-sterile Drug Products
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.
Specifically, on 11/13/2023, during a review of selected <Redacted B6> aseptically sterile lots that were produced within your firm's Formulation Room <R edacted B4> designated ISO 5 LAFUs (Asset IDs E4252 & E4689), the following poor aseptic techniques wer e ob served <Redacted B4> A. During the aseptic production of Lipo (MIC) 30ml, processed on 10/31/2023, Lot 186017, BUD 04/24/2024, we observed the following deficiencies within your firm's ISO 5 LAF <Redacted B4> Asset ID E4252):
1. Sterile compounding technician was observed reaching over open finished drug filled vials while filling empty vials.
2. Your firm's sterile compounding technician was observed dumping aluminum caps from <Redacted B4> bag over top rubber stoppered vials and placing the caps on top of the stoppered vials while the <Redacted B4> sterile compounding technician filled empty sterile vials.
B. ...
Observation 2
Personnel infrequently changed and sanitized gloves to prevent contamination.
Specifically,
A. On 10/23/2023, during observation of your firm's automated vial filling operation within your firm's ISO 5 Cleanroom, for the drug product, NAD+ (Nicotinamide Adenine Dinucleotide) (L YO) 500mg Injectable, Lot 186001, BUD 10/15/2024 within the firm's ISO 5 Filling Room, we observed the firm's sterile compounding technician center, perform a designated task within the <Redacted B4> filling machine, and restart the ISO filling machine without disinfecting their gloves prior to returning to stacking the vials into the <Redacted B4> containers. Additionally, other technicians were observed entering the ISO 5 Classified production area, touching the entry door and proceeded to perform tasks within the room without disinfecting their gloves.
B. ...
Observation 3
Use of ingredients not intended for pharmaceutical use in sterile drug production.
Specifically,
A. During a walk-though of your firm's warehouse for the storage of APis and drug components, we found the following API/drug component, Edetate Disodium Dihydt·ate (EDTA) USP, Lot <Redacted B4> Expiry 3/24/2026, QC Approval 8/11/23, with a printed affixed label bearing the text, "Not for Use As Drug/API, or Drug Product". The product was received through your firm's unapproved supplier. The API manufacturer does not have an active registration with the FDA and is listed under Import Alert 66-79. The importer/distributor was also found not to have an active registration. Your firm used the "Not for Use as Drug/API or Drug Product" to compound the following sterile drug product:
B. During a review of your firm's sterile drug production logs, the following finished sterile drugs products were selected in support of your firm's use of the non-pharmaceutical grade components:
1. Edetate Disodium Preservative Free (30 mL) 150 mg/mL Injectable, Lot 185526, Expiry 10/4/2024 Q!Y: <Redacted B4> vials, using the API, EDTA Disodium Salt Dihydrate <Redacted B4> CAS No. ...
Observation 4
Failure to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO 5 area.
Specifically, your firm's <Redacted B4> management reported it has no data to ensure clean/deactivation reagents and methods used within the ISO 5 Cleanroom for the <Redacted B4> filling/ stoppering/ capping equipment is adequate to prevent cross contamination of hazardous and non-hazardous sterile finished drug products. Your firm's quality manager reported all sterile drug products undergo sterility, endotoxin, and potency testing only. No other laboratory testing is performed to ensure cleaning effectiveness and deactivation of hazardous APis and or excipients in the prevention of cross contamination.
Observation 5
Inadequate routine environmental monitoring in the ISO 5 area and classified areas.
Specifically, during a review of your firm's environmental sampling results for your firm's ISO 5 classified areas and equipment, we found your firm's frequency for performing EM surface and viable air sampling is inadequate for ensuring adequacy for aseptic processing. For example, your firm performs EM surface and variable air sampling in your ISO 5 Classified Cleanroom and ISO 5 LAFUs where your firm conducts aseptic manipulations, the <Redacted B4> vial filling, stoppering, and capping <Redacted B4>. Your firm's COO reported your firm performs their <Redacted B4> to sterilize the non-sterile drug product within the ISO 5 <Redacted B4>. Your firm's management was unable to provide justification for the difference in frequency for EM sampling within the ISO 5 Classified areas and equipment. Your firm's management reported the firm follows the written procedure, Aseptic Environmental Sampling Plan SOP, A-SOP-QUA-0006, which documents EM sampling frequencies.
Observation 6
Inadequate post-use <Redacted B4> testing on <Redacted B4> used to sterilize drug products.
Specifically, during a review of our firm's non-conformances we found your firm initiated a total of 4 Non-conformance reports for <Redacted B4> failures for <Redacted B4> used during the <Redacted B4> process. Your firm's reports documented only 1 out of the 44-H lots underwent a <Redacted B4>, process, the remaining <Redacted B4> lots were released based on the <Redacted B4> which occurred in your firm's Formulation Rooms . For example, your firm qualify unit reviewed, approved, and released finished drug product <Redacted B4> within your firm's inadequately EM sampled ISO 5 <Redacted B4> in Formulation Room <Redacted B4>. Your firm's management reported all sterile drug products undergo a total of <Redacted B4>. The initial occurs after formulation within Formulation Room <Redacted B4>. The <Redacted B4> occurs prior to undergoing the filling, stoppering, and filling process steps. Initiates non-conformances documenting only undergoing <Redacted B4> that occurred within Formulation Room <Redacted B4> include:
A. ...
Observation 7
Specifically, your firm fail to use biological indicators to ensure your firm's glassware is endotoxin free by undergoing an adequate <Redacted B4>. Your firm's senior engineer reported biological indicators were only used during the cycle validation and temperature probe use for temperature monitoring and recording of processing temperatures. He continued in stating there is no defined revalidation process for the cycle and or temperature probe using biological indicators.
Observation 8
Compounding with components, containers or other materials that have not been verified to assure that they do not contribute endotoxin contamination that may be objectionable given the product's intended use.
Specifically, your firm management reported your firm assigns expiry date to all <Redacted B4> glassware used in the production of sterile drug products. Your firm's management failed to provide laboratory records/data in support of your firm's assigned expiry ensuring no endotoxins are present on the glassware used in drug production.
({£1-.fil
Inspection Jul 18, 2022 to Aug 5, 2022: 17 observations
- Firm on the cover
- Empower Clinic Services LLC dba Empower Pharmacy, 5980 W Sam Houston Pkwy N Ste 300, Houston, TX 77041 -5251
- FEI number
- 3011887629
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 1201 Main Street, Suite 7200 Dallas, TX 75202
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically, your Quality Unit (QU) failed to fulfill its duties and responsibilities. Examples include the following.
a)
Failure to investigate and/or thoroughly investigate complaints, deviations/non-conformances, and out of specification results (OOS) in a timely manner.
b) Failure to report adverse events within timeframes to the FDA.
c) There is a lack of documentation to show that all active pharmaceutical ingredients (API) and excipients are suitable for use in drug products, including control for endotoxins.
d)
Failure to have procedures in place for bringing ISO 5 and ISO 7 cleanrooms back to operating conditions following shut down of the air handling system, loss of differential pressure, and/or after maintenance/cleaning activities.
e)
Failure to implement Corrective and Preventive Actions identified by your firm. For example, CAPA No. 112001 contains an investigation into endotoxin failures that were attributed to L-Citrulline. Testing conducted of L-Citrulline from several suppliers revealed high endotoxin levels for at least two of the suppliers. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically, your firm has no procedure in place for returning the ISO 5 and ISO 7 cleanrooms to operating conditions following shut down of the air handling system and/or after maintenance activity. For example,
a) On July 5, 2021 , your firm noted a power outage had occurred that resulted in the HEPA filters for the ISO 5 and ISO 7 cleanroom suites being shut down with "no active air supply to the classified area". HEPA filter replacement and room certification was performed on July 2, 2021 . At some point on July 3, 2021 , the power went out as indicated by the loss of positive differential pressure between the cleanrooms. Your firm estimates the outage lasted for <Redac ted B4> hours. The same roof top unit (RTU) that had lost power again malfunctioned later in t he day on July , 021. A sterility failure oc curred for lot # <Redacted B4> of Ascorbic Acid Preservative Free 500 mg/ ml (30ml vial) th at wa s fi ll ed o n July 8, 202 1. ...
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, your firm has no documented justification for not monitoring all critical sites within the ISO 5 cleanroom where drug products are aseptically filled and/or, <Redacted B4> ensuring the location monitored is providing a meaningful sample, and ensuring all locations are samp e at appropriate frequencies. For example,
SOP T0S.14 Environmental Monitoring of Cleanrooms, version 03 effective 04/15/2021, is for the environmental monitoring that occurs during the production of a specific batch or lot of drug product.
For product that is <Redacted B4> such as Methylcobalamin (B12) Injection and Sermorelin Acetate lnjection your firm is not performing viable active air sampling at the point where open vials <Redacted B4> and are then placed on a tray and carried across the room to the table where filling will occur. Your firm is not consistently performing viable active air sampling at the site (table) where the open vials are filled and <Redacted B4>. ...
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
a)
Your firm ha s no documented ju stification for n ot <Redact ed B4> the <Redacted B4> us ed to hold sterilized <Redacted B4> for <Redacted B4> aseptically filled drug products that are filled using the <Redacted B4> filter. Your firm is only wiping the <Redacted B4> with <Redacted B4> before use.
b) We observed rust and/or discoloration that appeared to be rust on the shelves and wheels of carts and the tables located in the ISO 5 Cleanroom where aseptic drug products are filled.
c)
The legs of the tables located in the ISO 5 cleanroom are not a smooth cleanable surface. The height of the tables can be adjusted using <Redacted B4>
Observation 5
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, your firm is not performing investigations into all deviations (non-conformances), out of specification (OOS) results, and complaints received. Your firm is also not retaining all correspondence received and sent to the complainant. For example,
a) Since August 2021 , your firm has received at least seven (7) complaints regarding drug products that were received without labels. Your firm has no documented investigation into any of these complaints.
b) Since September 2021 , your firm has received at least 12 complaints regarding particles/particulates, crystallization, and/or precipitate found in several lots of Coenzyme Q-10 (Ubidecarenone) Injection. Your firm has not performed an investigation into the majority of these complaints and has advised the complainants to re-warm the product to see if the precipitate goes back into solution. ...
Observation 6
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
i.
Specifically, your firm has no procedure for integrity testing and replacement, including frequency, of the <Redacted B4> used to the <Redacted B4> and used during <Redacted B4> of aseptically filled drug products. The last time the <Redacted B4> was replaced was September 3, 2019. Your firm has documentation of any integrity testing of the <Redacted B4> when it was changed. <Redacted B4> products include Methylcobalamin (B12) injection and Semorelin Acetate injection.
Observation 7
Written procedures are not established and followed that describe the in-process controls, tests and examinations to be conducted on appropriate samples of in-process materials of each batch.
Specifically,
b) Your firm is not conducting an AQL sampling and inspection of containers after 100% visual inspection.
Observation 8
Written procedures are lacking which describe in sufficient detail the receipt, handling, sampling, testing, approval and rejection of components.
Specifically,
a)
Your firm has no documentation to show that all bulk drug substances and excipients are appropriate for use in drug products. All lots listed have been released and distributed. For example,
• Mecocobalamin (Methylcobalamin) lot <Re dact ed B4> - Certifica te of A nalys is ( CoA) from m anufa ctur er s tates "No t for Drug Use". This lot was used to make lot #s <Redacted B4>. <Redacted B4> and <Redacted B4> of Methylcobalamin (B12) Injection - 10,000 mcg/vial on <Redacted B4> (mixing), <Redacted B4> (filling and <Redacted B4>), and <Redacted B4> <Redacted B4>).
• Cyanocobalamin (Vitamin 812) batch # <Redacted B4> -CoA from manufacturer states "Not for Drug Use". This product is used to make s teril e drug produ cts such as lot # <R edacted B4> of L ipo- 8 I njection made o n and lot # <Re dacted B4> of Cyan ocobalamin (B12) injection, 2,000 mcg/ml made on <Redacted B4>
• Ascorbic Acid USP < Redacted B4> Source) lot # <Redacted B4> used to make lot of Ascorbic Acid Injection Preserved 500mg/mL. ...
Observation 9
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically, media fills for the <Redacted B4> product Methylcobalamin (B12) injection do not simulate worst case. For example, your firm compounds solution to fill <Redacted B4> vials and then uses it to fill <Redacted B4> sublots of <Redacted B4> vials. <Redacted B4> vials are placed in the <Redacted B4>after each sublot is filled and the entire <Redacted B4> vials are <Redacted B4>. Your media fill is only simulating the filling of <Redacted B4> vials, placing the <Redacted B4> <Redacted B4> vials in the <Redacted B4>, and then <Redacted B4> those <Redacted B4> vials. The media fill does not stimulate the filling of the <Redacted B4> sublots and placing all <Redacted B4> vials in the <Redacted B4>.
Observation 10
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards and test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically,
a) Your firm uses multiple manufacturers of several active pharmaceutical ingredients (API). Your firm has not performed method suitability for sterility testing on formulations for all API manufacturers. For example,
i.
Your firm has used <Redacted B4> different manufacturers of Taurine (API). Your firm has <Redacted B4> contract labs who perform sterility testing of Taurine Injection 50mg/ml however, method suitability has only been performed for formulations containing one of the <Redacted B4> suppliers. Lot of <Redacted B4> Taurine Injection 50mg/ml was made using the API supplied ttie manufacturer for which method suitability has not been performed. This lot has been released and distributed.
ii.
Your firm has <Redacted B4> contract labs who can perform sterility testing of Vitami B-Complex injection that contains Thiamine HCL. ...
Observation 11
Drug product containers and closures were not clean and sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
Specifically,
a) Your firm has not performe d a hold time study to show the <Redacted B4> expiration date you have assigned to <Redacted B4> after <Redacted B4> is appropriate. For example, the <Redacted B4> used for lot <Redacted B4> of Semorelin Acetate injection filled and <Redacted B4> on 06/06/2022 were <Redacted B4> on 04/21/2022 lot <Redacted B4.
b) Your firm is not using final rinse water that meets the specifications of WFI , USP for washing of vials to be used for filling sterile injectable drug products.
Observation 12
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to re lease.
Sp ecifically, your firm does not perform testing of non-sterile drug products if the number of units made per lots <Redacted B4>. For example, from March 2020 until July 2022, your firm has made approximately <Redacted B4> lots of Ketamine Nasal Spray (2mL, 5mL and 15mL sizes). None of these lots has been tested for potency assay of active ingredient).
Observation 13
Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.
Specifically, your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six-month period. Specifically, <Redacted B4> products of various strengths and formulations were compounded at your outsourcing facility and not identified on your report dated June 2022.
Examples of products include:
• <Redacted B4> - NIA CINAMIDE / SODIUM HYALURONATE / TRETINOIN (30 ML) 4/0.5/0.025% CREAM
ROSACEA CREAM 3.3.1 (IVERMECTIN / METRONIDAZOLE / NIACINAMIDE) (30 ML)
< Redacted B4> - TRI - ROSACEA CREAM - AZELAIC AC ID / IVERMECTIN / METRONI DAZOLE / NIACINAMIDE (30 ML) 5/1/14% CREAM • <REDACTED B4> (ESTRIOL) (30 ML) 0.3% CREAM
PS 1.4.1 (COAL TAR SOLUTION / SALICYLIC ACID / TRIAMCINOLONE ACETONIDE / UREA) (30 ML) 5/5/0.16/10% CREAM
MELASMA CREAM 4.3.2 (HYDROQUINONE / TRETINOIN / TRIAMCINOLONE ACETONIDE) (30 ML)4/0.025/0.1% CREAM
• ECZEMA OINTMENT 1.2.2 (NIACINAMIDE / TACROLIMUS) (30 ML) 4/0.1 % OINTMENT
• DERMATITIS, SEBORRHEIC SHAMPOO 1.2.1 (CICLOPIROX / CLOBETASOL PROPIONATE) (1 20 ML) 0.77/0.05% SHAMPOO
Observation 14
Adverse drug experience information has not been reported to FDA.
Specifically, your outsourcing facility has not submitted adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under 21 CFR 310.305 as required by section 5038(b)(5). Your firm did not submit the following adverse event reports within 15 calendar days after first receiving information about the adverse event:
• INC-0000015002
• INC-0000023861
Observation 15
The labels of your outsourcing facility's drug products are deficient.
1. Specifically, the labels of your outsourcing facility's drug products do not include information required by section 5038(a)(10)(A). Specifically, the following information is not found on your drug product labels:
a) The statement "This is a compounded drug"·
• Example: <Redacted B4> Capsule
b) The date that the drug was compounded;
• Example: <Redacted B4> Capsule
c) The storage and handling instructions;
• Example: <Redacted B4> Capsule
d) The statement "Not for resale", and, if the drug is dispensed or distributed other than pursuant to a prescription for an individual identified patient, the statement "Office Use Only";
• Example: <Redacted B4> Capsule
e) A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. Examples:
• Ketamine Nasal Spray 100 mg/ml (10 mg/Spray):
• Ketamine Troche 200 mg:
• Estradiol Pellet 6 mg
• Rosacea Cream
• Tri-Rosacea Cream
• <Redacted B4> Capsule
The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(B). ...
Observation 16
Written procedures are not established and followed for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.
Specifically, your firm did not conduct an annual product review (APR) for any drug products in 2021 . The APR conducted in 2020 consisted of a review of three (3) batch records for each product regardless of the number of batches made during the year, and did not include a review of all quality information related to the product with the exception of the three lots reviewed. Your firm is not reviewing quality metrics for the entirety of products made over the period of review such as complaints, deviations, and finished product testing.
Observation 17
Bulk drug substances used by your outsourcing facility to compound drug products are not each manufactured by an establishment that is registered under section 510 as required by section 503B(a)(2)(C).
Specifically, examples of bulk drug substances used by your firm that are from manufacturers that have not registered with FDA include the following. All finished product lots listed have been released and distributed.
i.
L-Citrulline batch #<Redacted B4> (supplier lot #<Redacted B4>) used to make lot <Redacted B4> of Tri-Amino Injection.
ii. Riboflavin 5' -Phosphate lot <Redacted B4> used to make lot # <Redacted B4> of Riboflavin (B2) Injection 10mg/ml on 05/23-24/2022.
L-Methionind batch # <Redacted B4> used to make lot <Redacted B4> of Lipo-B Injection (30ml).
1v. Inositol batch # <Redacted B4> used to make lot # <Redacted B4> of Lipo-8 Injection (30ml).
v.
Choline Chloride lot # <Redacted B4> used to make lot <Redacted B4> of Lipo-B Injection (30ml).
vi. Pyridoxine HCI batch # <Redacted B4> used to make lot #s <Redacted B4> and <Redacted B4> of Vitamin B-Complex Injection.
vii. ...
Earlier Form 483s
- Inspection Feb 12, 2020 to Mar 6, 2020: 6 observations, first: “Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.” PDF
- Inspection Nov 9, 2015 to Nov 25, 2015: 7 observations, first: “"'·:". There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.” PDF
The text of every observation in these is in the form-483-observations.csv download.
Linked 483s whose text is not shown
- Oct 24, 2018: FDA document 111056: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
The Texas State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status | Prior disciplinary orders (file flag) |
|---|---|---|---|---|---|
| 26444 | Community Sterile Compounding | EMPOWER PHARMACY | HOUSTON | Active | No |
What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NRP 2567 | Non Resident Pharmacy | Empower Pharmacy | Houston, TX | Active |
| NSC 101695 | Non Resident Licensed Sterile Compounding | Empower Pharmacy | Houston, TX | Delinquent |
- Jan 18, 2023: “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for four years subject to the terms and conditions in the decision.”, license NRP 2567, case AC 7117, Empower Pharmacy, Houston, TX. Board list
- Jan 18, 2023: “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended.”, license NRP 1834, case AC 7117, Empower Pharmacy, Houston, TX. Board list
- Jan 18, 2023: “Through a disciplinary action of the Board, the license is revoked, the revocation stayed, and the license is placed on probation for four years subject to the terms and conditions in the decision.”, license NSC 101695, case AC 7117, Empower Pharmacy, Houston, TX. Board list
- Jan 18, 2023: “Through a disciplinary action of the Board, the license is revoked and the right to practice or operate has ended.”, license NSC 100984, case AC 7117, Empower Pharmacy, Houston, TX. Board list
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 6131 | OSP | Empower Pharmacy | Houston, TX | Active |
- Aug 8, 2023: “CLS Stipulation”, license OSP 6131, case 2023-1306, Empower Pharmacy, Houston, TX. Board document
- Oct 12, 2021: “CLS Letter of Admonition”, license OSP 6131, case 2021-3810, Empower Pharmacy, Houston, TX. Board document
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054018298 | LICENSED PHARMACY | EMPOWER CLINIC SERVICES LLC | HOUSTON, TX | ACTIVE |
| 054021486 | LICENSED PHARMACY | EMPOWER CLINIC SERVICES LLC | HOUSTON, TX | ACTIVE |
- Jun 21, 2024: “Reprimand”, license 054018298, case 2022008353, EMPOWER CLINIC SERVICES LLC, HOUSTON, TX. Reason given in the record: “pharmacy license reprimanded; eff 06/09/20.” Board list
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0002564 | NONRESIDENT PHARMACY | EMPOWER PHARMACY | HOUSTON, TX | ACTIVE (CURRENT) |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0001344 | Non Resident Pharmacy | Empower Clinic Services, L.L.C. | HOUSTON, TX | Active |
| AA-0000030 | Outsourcing Facility-Pharmacy | Empower Clinic Services, L.L.C. | HOUSTON, TX | Active |
| A9-0002430 | Non Resident Pharmacy | Empower Pharmacy | HOUSTON, TX | Expired |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301012675 | Pharmacy | Empower Clinic Services, LLC | Houston, TX | Active |
| 5301012722 | Pharmacy | Empower Clinic Services, L.L.C. | Houston, TX | Active |
| 5301013382 | Pharmacy | Empower Clinic Services, L.L.C. | Houston, TX | Active |
GLP-1 warning letters
FDA’s posted warning letters that name a GLP-1 drug include 1 letter to Empower Clinic Services, LLC dba Empower Pharmacy. See the Empower Clinic Services, LLC dba Empower Pharmacy record page for those letters and any recalls.
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Sep 18, 2026 | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA warning letters (fda.gov full-text search)
- Texas State Board of Pharmacy license file
- California State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- Texas State Board of Pharmacy disciplinary records
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.